Advertisement

The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?

  • Naranie ShanmuganathanEmail author
  • Susan Branford
Chronic Myeloid Leukemias (G Saglio, Section Editor)
  • 13 Downloads
Part of the following topical collections:
  1. Topical Collection on Chronic Myeloid Leukemias

Abstract

Purpose of Review

Identification of the BCR-ABL1 fusion oncogene in patients diagnosed with chronic myeloid leukemia (CML) led to the development of targeted therapy responsible for the dramatic survival benefits observed in the past two decades. However, despite these revolutionary findings, there remains marked disparity in patient outcomes. Why do some patients present de novo while others evolve to the more aggressive stages of CML? Why can select patients successfully discontinue therapy as part of a treatment-free remission attempt whereas others fail to meet specific molecular milestones?

Recent Findings

BCR-ABL1 kinase mutations are only identified in approximately 50% of patients with poor responses and disease progression, suggesting the presence of alternative resistance mechanisms. Numerous institutions have identified the presence of additional genomic events in addition to BCR-ABL1 with the increasing availability of next-generation sequencing.

Summary

We explore the potential pathways and events that may cooperate with BCR-ABL1 to answer these questions but also challenge the fundamental tenet that BCR-ABL1 is always the sole event initiating CML.

Keywords

Next-generation sequencing Mutations Disease progression Resistance 

Notes

Funding Information

N.S. received scholarship funding from the Royal Adelaide Hospital Research Foundation Dawes Scholarship. S.B. received support from the National Health and Medical Research Council of Australia (APP1104425).

Compliance with Ethical Standards

Conflict of Interest

N.S. received honoraria from Novartis and Bristol-Myers Squibb and travel and accommodation expenses from Novartis, Gilead, Amgen and Janssen. S.B. is a member of the advisory boards of Qiagen, Novartis and Bristol-Myers Squibb and received honoraria from Qiagen, Novartis, Bristol-Myers Squibb and Cepheid.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Valent P, Kern W, Hoermann G, Milosevic Feenstra JD, Sotlar K, Pfeilstöcker M, et al. Clonal hematopoiesis with oncogenic potential (CHOP): separation from CHIP and roads to AML. Int J Mol Sci. 2019;20(3):789.  https://doi.org/10.3390/ijms20030789.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Knudson AG. Two genetic hits (more or less) to cancer. Nature reviews Cancer. 2001;1(2):157–62.  https://doi.org/10.1038/35101031.CrossRefPubMedGoogle Scholar
  3. 3.
    Goldman JM, Melo JV. Chronic myeloid leukemia — advances in biology and new approaches to treatment. N Engl J Med. 2003;349(15):1451–64.  https://doi.org/10.1056/NEJMra020777.CrossRefPubMedGoogle Scholar
  4. 4.
    Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122.  https://doi.org/10.1182/blood-2013-05-501569.CrossRefGoogle Scholar
  5. 5.
    Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405.  https://doi.org/10.1182/blood-2016-03-643544.CrossRefPubMedGoogle Scholar
  6. 6.
    Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21.  https://doi.org/10.1056/NEJMoa1516192.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348.  https://doi.org/10.1056/NEJMoa022457.CrossRefGoogle Scholar
  8. 8.
    Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–70.  https://doi.org/10.1056/NEJMoa1002315.CrossRefPubMedGoogle Scholar
  9. 9.
    Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251–9.  https://doi.org/10.1056/NEJMoa0912614.CrossRefPubMedGoogle Scholar
  10. 10.
    Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Onc. 2012;30.  https://doi.org/10.1200/jco.2011.38.7522.CrossRefGoogle Scholar
  11. 11.
    Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–27.  https://doi.org/10.1056/NEJMoa1609324.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30(5):1044–54.  https://doi.org/10.1038/leu.2016.5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Onc. 2016.  https://doi.org/10.1200/jco.2015.64.8899.CrossRefGoogle Scholar
  14. 14.
    • Radich JP. The biology of CML blast crisis. ASH Education Program Book. 2007;2007(1):384–91.  https://doi.org/10.1182/asheducation-2007.1.384. One of the earliest reviews into genes cooperating with BCR-ABL1 in blast crisis CML.CrossRefGoogle Scholar
  15. 15.
    Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029–35.  https://doi.org/10.1016/s1470-2045(10)70233-3.CrossRefPubMedGoogle Scholar
  16. 16.
    Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 2013;122(4):515–22.  https://doi.org/10.1182/blood-2013-02-483750.CrossRefPubMedGoogle Scholar
  17. 17.
    Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747–57.  https://doi.org/10.1016/S1470-2045(18)30192-X.CrossRefPubMedGoogle Scholar
  18. 18.
    Daley G, Van Etten R, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (New York, NY). 1990;247(4944):824–30.  https://doi.org/10.1126/science.2406902.CrossRefGoogle Scholar
  19. 19.
    Zhang X, Ren R. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia. Blood. 1998;92(10):3829–40.CrossRefGoogle Scholar
  20. 20.
    Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA. Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood. 1981;58(1):158–63.CrossRefGoogle Scholar
  21. 21.
    Ismail SI, Naffa RG, Yousef AM, Ghanim MT. Incidence of bcr-abl fusion transcripts in healthy individuals. Mol Med Reports. 2014;9(4):1271–6.  https://doi.org/10.3892/mmr.2014.1951.CrossRefGoogle Scholar
  22. 22.
    Boquett JA, Alves JR, de Oliveira CE. Analysis of BCR/ABL transcripts in healthy individuals. Genet Mol Res. 2013;12(4):4967–71.  https://doi.org/10.4238/2013.October.24.8.CrossRefPubMedGoogle Scholar
  23. 23.
    Basecke J, Griesinger F, Trumper L, Brittinger G. Leukemia- and lymphoma-associated genetic aberrations in healthy individuals. Ann Hematol. 2002;81(2):64–75.  https://doi.org/10.1007/s00277-002-0427-x.CrossRefPubMedGoogle Scholar
  24. 24.
    Hehlmann R, Lauseker M, Saußele S, Pfirrmann M, Krause S, Kolb HJ, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia. 2017;31:2398–406.  https://doi.org/10.1038/leu.2017.253.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003;102(4):1160–8.  https://doi.org/10.1182/blood-2003-01-0123.CrossRefPubMedGoogle Scholar
  26. 26.
    Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1–positive chronic myeloid leukemia. Blood. 2009;113(8):1619–30.  https://doi.org/10.1182/blood-2008-03-144790.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    •• Kim T, Tyndel MS, Kim HJ, Ahn JS, Choi SH, Park HJ, et al. Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy. Blood. 2017;129(1):38–47.  https://doi.org/10.1182/blood-2016-04-708560. Exploration of the genomic landscape of CML.CrossRefPubMedGoogle Scholar
  28. 28.
    • Soverini S, Branford S, Nicolini FE, Talpaz M, Deininger MW, Martinelli G, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res. 2014;38(1):10–20.  https://doi.org/10.1016/j.leukres.2013.09.011. Investigation into the implication of kinase domain mutations in CML.CrossRefPubMedGoogle Scholar
  29. 29.
    Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012;119(10):2234–8.  https://doi.org/10.1182/blood-2011-08-375535.CrossRefPubMedGoogle Scholar
  30. 30.
    Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011.  https://doi.org/10.1182/blood-2010-12-326405.CrossRefGoogle Scholar
  31. 31.
    Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Onc. 2011;29(32):4250–9.  https://doi.org/10.1200/jco.2011.35.0934.CrossRefGoogle Scholar
  32. 32.
    • Fabarius A, Leitner A, Hochhaus A, Müller MC, Hanfstein B, Haferlach C, et al. Impact of ACA at diagnosis on prognosis of CML: long-term observation from 1151 patients of the randomized CML Study IV. Blood. 2011;118(26):6760–8.  https://doi.org/10.1182/blood-2011-08-373902. Impact of additional cytogenetic abnormalities on outcomes in CML.CrossRefPubMedGoogle Scholar
  33. 33.
    • Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood. 2012;120(4):761–7.  https://doi.org/10.1182/blood-2011-10-384651. Impact of additional cytogenetic abnormalities on outcomes in CML.CrossRefPubMedGoogle Scholar
  34. 34.
    • Alhuraiji A, Kantarjian H, Boddu P, Ravandi F, Borthakur G, Di Nardo C, et al. Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol. 2018;93(1):84–90.  https://doi.org/10.1002/ajh.24943. Impact of additional cytogenetic abnormalities on outcomes in CML.CrossRefPubMedGoogle Scholar
  35. 35.
    Milojkovic D, Apperley J. Mechanisms of resistance to imatinib and second-generation tyrosine inhibitors in chronic myeloid leukemia. Clin Canc Research. 2009;15(24):7519–27.  https://doi.org/10.1158/1078-0432.ccr-09-1068.CrossRefGoogle Scholar
  36. 36.
    Eadie LN, Hughes TP, White DL. Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. Clinical Pharmacology & Therapeutics. 2014;95(3):294–306.  https://doi.org/10.1038/clpt.2013.208.CrossRefGoogle Scholar
  37. 37.
    White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Onc. 2010;28(16):2761–7.  https://doi.org/10.1200/jco.2009.26.5819.CrossRefGoogle Scholar
  38. 38.
    Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004;103(11):4010–22.  https://doi.org/10.1182/blood-2003-12-4111.CrossRefPubMedGoogle Scholar
  39. 39.
    •• Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease. Blood. 2018;132(9):948–61.  https://doi.org/10.1182/blood-2018-02-832253. Exploration of the genomic landscape of CML.CrossRefPubMedGoogle Scholar
  40. 40.
    • Ilaria RL. Pathobiology of lymphoid and myeloid blast crisis and management issues. ASH Education Program Book. 2005;2005(1):188–94.  https://doi.org/10.1182/asheducation-2005.1.188. Exploration of blast crisis pathogenesis.CrossRefGoogle Scholar
  41. 41.
    • Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res. 2006;12(24):7374–9.  https://doi.org/10.1158/1078-0432.ccr-06-1516. Impact of kinase domain mutations in CML.CrossRefPubMedGoogle Scholar
  42. 42.
    Feinstein E, Cimino G, Gale RP, Alimena G, Berthier R, Kishi K, et al. p53 in chronic myelogenous leukemia in acute phase. Proceedings of the National Academy of Sciences of the United States of America. 1991;88(14):6293–7.  https://doi.org/10.1073/pnas.88.14.6293.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ahuja H, Bar-Eli M, Advani SH, Benchimol S, Cline MJ. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(17):6783–7.  https://doi.org/10.1073/pnas.86.17.6783.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest. 1991;87(6):2042–7.  https://doi.org/10.1172/JCI115234.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. 2019; (accepted for publication).Google Scholar
  46. 46.
    Peterson LF, Mitrikeska E, Giannola D, Lui Y, Sun H, Bixby D, et al. p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells. Leukemia. 2011;25(5):761–9.  https://doi.org/10.1038/leu.2011.7.CrossRefPubMedGoogle Scholar
  47. 47.
    Serra A, Gottardi E, Della Ragione F, Saglio G, Iolascon A. Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia. Br J Haematol. 1995;91(3):625–9.CrossRefGoogle Scholar
  48. 48.
    Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, Weissmann S, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia. 2011;25(3):557–60. http://www.nature.com/leu/journal/v25/n3/suppinfo/leu2010298s1.html.CrossRefGoogle Scholar
  49. 49.
    Savona M, Talpaz M. Getting to the stem of chronic myeloid leukaemia. Nature Reviews Cancer. 2008;8:341–50.  https://doi.org/10.1038/nrc2368.CrossRefPubMedGoogle Scholar
  50. 50.
    Williams RT, Sherr CJ. BCR–ABL and CDKN2A: a dropped connection. Nature Reviews Cancer. 2008;8:563.  https://doi.org/10.1038/nrc2368-c1.CrossRefPubMedGoogle Scholar
  51. 51.
    Marke R, van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565–74.  https://doi.org/10.3324/haematol.2017.185603.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Perrotti D, Jamieson C, Goldman J, Skorski T. Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010;120(7):2254–64.  https://doi.org/10.1172/JCI41246.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24:1128–38.  https://doi.org/10.1038/leu.2010.69.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Chou WC, Huang HH, Hou HA, Chen CY, Tang JL, Yao M, et al. Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. Blood. 2010;116(20):4086–94.  https://doi.org/10.1182/blood-2010-05-283291.CrossRefPubMedGoogle Scholar
  55. 55.
    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.  https://doi.org/10.1182/blood-2016-08-733196.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Roche-Lestienne C, Marceau A, Labis E, Nibourel O, Coiteux V, Guilhot J, et al. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia. Leukemia. 2011;25(10):1661–4.  https://doi.org/10.1038/leu.2011.139.CrossRefPubMedGoogle Scholar
  57. 57.
    Avellino R, Delwel R. Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation. Blood. 2017;129(15):2083–91.  https://doi.org/10.1182/blood-2016-09-687822.CrossRefPubMedGoogle Scholar
  58. 58.
    Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, et al. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004;21(6):853–63.  https://doi.org/10.1016/j.immuni.2004.11.006.CrossRefPubMedGoogle Scholar
  59. 59.
    Kagita S, Uppalapati S, Gundeti S, Digumarti R. Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia. Jpn J Clin Oncol. 2015;45(8):749–54.  https://doi.org/10.1093/jjco/hyv064.CrossRefPubMedGoogle Scholar
  60. 60.
    Tavor S, Park DJ, Gery S, Vuong PT, Gombart AF, Koeffler HP. Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation. The Journal of biological chemistry. 2003;278(52):52651–9.  https://doi.org/10.1074/jbc.M307077200.CrossRefPubMedGoogle Scholar
  61. 61.
    Najfeld V, Wisch N, Mascarenhas J, Issa L, Tripodi J, Sidhu M, et al. Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression. Cancer Genetics. 2011;204(3):165–70.  https://doi.org/10.1016/j.cancergencyto.2010.09.001.CrossRefPubMedGoogle Scholar
  62. 62.
    Ong ST, Pathiraja T, Javed A, Soh XXS, Malik S, Tan JHJ, et al. The genomic and epigenomic landscapes of blast crisis transformation in chronic myeloid leukemia. Blood. 2015;126(23):3737.CrossRefGoogle Scholar
  63. 63.
    Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, Cazzolli H, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood. 2011;117(21):e198–206.  https://doi.org/10.1182/blood-2010-06-292433.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Schuurhuis GJ, Heuser M, Freeman S, Bene MC, Buccisano F, Cloos J, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131(12):1275–91.  https://doi.org/10.1182/blood-2017-09-801498.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Schmidt M, Rinke J, Schafer V, Schnittger S, Kohlmann A, Obstfelder E, et al. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status. Leukemia. 2014;28(12):2292–9.  https://doi.org/10.1038/leu.2014.272.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Naranie Shanmuganathan
    • 1
    • 2
    • 3
    • 4
    • 5
    Email author
  • Susan Branford
    • 1
    • 2
    • 3
    • 6
    • 7
  1. 1.Department of Genetics and Molecular PathologySA PathologyAdelaideAustralia
  2. 2.Precision Medicine ThemeSouth Australian Health and Medical Research InstituteAdelaideAustralia
  3. 3.School of MedicineUniversity of AdelaideAdelaideAustralia
  4. 4.Department of HaematologyRoyal Adelaide Hospital and SA PathologyAdelaideAustralia
  5. 5.School of Health SciencesUniversity of South AustraliaAdelaideAustralia
  6. 6.School of Pharmacy and Medical ScienceUniversity of South AustraliaAdelaideAustralia
  7. 7.School of Biological SciencesUniversity of AdelaideAdelaideAustralia

Personalised recommendations